Skip to main content
Published Online:https://doi.org/10.3928/23258160-20160901-01
First page image

  • 1.Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998–1003.10.1016/S0161-6420(98)96025-0

    CrossrefGoogle Scholar
  • 2.No authors listed. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985; 103(12):1796–1806.10.1001/archopht.1985.01050120030015

    CrossrefGoogle Scholar
  • 3.Diabetic Retinopathy Clinical Research NetworkElman MJ, Aiello LP, et al.Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117(6):1064–1077.10.1016/j.ophtha.2010.02.031

    CrossrefGoogle Scholar
  • 4.Nguyen QD, Brown DM, Marcus DM, et al.Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789–801.10.1016/j.ophtha.2011.12.039

    CrossrefGoogle Scholar
  • 5.Rajendram R, Fraser-Bell S, Kaines A, et al.A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012; 130(8):972–979.10.1001/archophthalmol.2012.393

    CrossrefGoogle Scholar
  • 6.Brown DM, Schmidt-Erfurth U, Do DV, et al.Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015; 122(10):2044–52.10.1016/j.ophtha.2015.06.017

    CrossrefGoogle Scholar
  • 7.Dugel P. EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME. Paper presented at the American Academy of Ophthalmology Retina Subspecialty Day; November 13–17, 2015; Las Vegas, NV.

    Google Scholar
  • 8.Gonzales V, Augustin A, Campbell J, et al.EARLY: Anti-VEGF treatment response at week 12 and long term outcomes in DME. Paper presented at World Ophthalmology Congress; February 5–9, 2016; Guadalajara, Mexico.

    Google Scholar
  • 9.Boyer DS, Yoon YH, Belfort R, et al.Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121(10):1904–1914.10.1016/j.ophtha.2014.04.024

    CrossrefGoogle Scholar
  • 10.Campochiaro PA, Brown DM, Pearson A, et al.Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012; 119(10):2125–2132.10.1016/j.ophtha.2012.04.030

    CrossrefGoogle Scholar
  • 11.Bressler SB, Qin H, Beck RW, et al.Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012; 130(9):1153–1161.10.1001/archophthalmol.2012.1107

    CrossrefGoogle Scholar
  • 12.Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008; 115(9):1447–1459.10.1016/j.ophtha.2008.06.015

    CrossrefGoogle Scholar
  • 13.Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delayed system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina. 2015; 35(8):1604–1614.10.1097/IAE.0000000000000533

    CrossrefGoogle Scholar
  • 14.Figueira J, et al.RESPOND study: Interim six month results. Presented at the 2015 EURETINA Congress; September 17–20, 2015; Nice, France.

    Google Scholar
  • 15.Campochiaro PA. Results of the AKB-9778 in the treatment of Diabetic retinopathy: Results from the TIME-2 Study. Presented at Subspecialty Day, American Academy of Ophthalmology; November 2015, Las Vegas, NV.

    Google Scholar
  • 16.Singer MA. Results of the Optimeyes phase 2 study. Presented at World of Ophthalmology Congress; February 2016; Guadalajara, Mexico.

    Google Scholar
  • 17.A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema. ClinicalTrials.gov identifier: NCT02302079.

    Google Scholar
  • 18.A phase 2 randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin and focal laser photocoagulation in the treatment of diabetic macular edema. ClinicalTrials.gov identifier: NCT02348918.

    Google Scholar
  • 19.Anti-vascular endothelial growth factor plus anti-angiopoietin 2 in fixed combination therapy: evaluation for the treatment of diabetic macular edema (RUBY). ClinicalTrials.gov identifier: NCT02712008.

    Google Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×
  • Published online9/1/16 12:00 AM
  • __article__history--ppub9/1/16 12:00 AM